The Director General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus held meeting with WHO pandemic experts via video conferencing at the WHO headquarters in Geneva, Switzerland.
Referring to the provisional results of the Solidarity Trial in which the Covid-19 therapeutics were evaluated by the organization, Ghebreyesus said that the antiviral drug “Remdesivir”, hydroxychloroquine and the lopinavir / ritonavir combination used in the treatment of AIDS had little effect on deaths and hospital stay due to Covid-19, or it turned out to have no effect.
Ghebreyesus stated that despite the negative results, the Solidarity Trial launched by WHO in March with the participation of approximately 13 thousand volunteers in 500 hospitals in 30 countries will continue.
Stating that the Solidarity Trial recruits nearly 2000 patients each month and will continue other treatments, including monoclonal antibodies and new antivirals, Ghebreyesus said, “Currently, the corticosteroid dexamethasone is still the only therapeutic agent that has been shown to be effective against COVID-19 in patients with severe disease.” said.
Ghebreyesus reminded that around 3.5 million severe seasonal flu cases and around 650 thousand respiratory-related deaths occur every year in the world, and said:
“This year, the number of cases of seasonal flu and deaths was “lower than usual due to the measures established to contain the coronavirus. It cannot be assume the same will happen in the northern hemisphere flu season.”
The WHO Director-General also warned that the demand for flu vaccine may exceed supply.